Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.60 |
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14662754 | 0.97 | PTGS2 (0.60) | PTGS2FABP4PTGS1MAPK1SMN1; SMN2 | |
| SCHEMBL10479480 | 0.86 | GRIA2 (0.46) | PTGS2FABP4PTGS1SMN1; SMN2CYP1A2 | |
| SCHEMBL10479481 | 0.86 | PTGS2 (0.57) | PTGS2FABP4PTGS1SMN1; SMN2CYP1A2 | |
| SCHEMBL16517192 | 0.84 | PTGS2 (0.45) | PTGS2FABP4PTGS1MAPK1SMN1; SMN2 | |
| SCHEMBL5812502 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1CYP1A2CYP2C9GRIA2 | |
| SCHEMBL10479738 | 0.83 | GRIA2 (0.46) | PTGS2FABP4PTGS1CYP1A2CYP2C9 | |
| SCHEMBL25434903 | 0.83 | TP53 (0.55) | PTGS2FABP4PTGS1HTTALDH1A1 | |
| SCHEMBL10479510 | 0.82 | KDM4E (0.49) | PTGS2FABP4SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL16517111 | 0.82 | PTGS2 (0.45) | PTGS2FABP4PTGS1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10479499 | 0.81 | ALDH1A1 (0.58) | PTGS2FABP4HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| EP-3423452-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | PTGS2 3528/4885FABP4 2283/4885PTGS1 2973/4885 |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | PTGS2 3528/4885FABP4 2283/4885PTGS1 2973/4885 |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | PTGS2 3528/4885FABP4 2283/4885PTGS1 2973/4885 |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | WNT1, CTNNB1, WNT3A | PTGS2 3528/4885FABP4 2283/4885PTGS1 2973/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | PTGS2 3528/4885FABP4 2283/4885PTGS1 2973/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | PTGS2 3039/4885FABP4 4242/4885PTGS1 3108/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | PTGS2 3528/4885FABP4 2283/4885PTGS1 2973/4885 |
| US-10723715-B2 | — | CTNNB1, WNT1, CTNNBL1 | PTGS2 3430/4885FABP4 191/4885PTGS1 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.